Appearance
The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future.
文献信息
| DOI | 10.3322/caac.21749 |
|---|---|
| PMID | 35969103 |
| 期刊 | CA: a cancer journal for clinicians |
| 影响因子 | 232.4 |
| JCR 分区 | Q1 |
| 发表年份 | 2023 |
| 被引次数 | 44 |
| 关键词 | 细胞减灭手术、热灌注腹腔化疗(HIPEC)、多模式管理、腹膜转移 |
| 文献类型 | Journal Article, Review |
| ISSN | 0007-9235 |
| 页码 | 49-71 |
| 期号 | 73(1) |
| 作者 | Jason M Foster, Chunmeng Zhang, Shahyan Rehman, Prateek Sharma, H Richard Alexander |
一句话小结
腹膜转移(PM)虽然被认为是较为罕见的肿瘤扩散模式,但其对患者的影响显著,传统治疗效果有限。本文回顾了现代多模式治疗(包括细胞减灭手术、热灼腹腔化疗和精准医学技术)在高频率PM肿瘤(如阑尾癌、结直肠癌等)中的应用,强调了这些方法在改善症状和生存期方面的潜力。
在麦伴科研 (maltsci.com) 搜索更多文献
细胞减灭手术 · 热灌注腹腔化疗(HIPEC) · 多模式管理 · 腹膜转移
摘要
腹膜转移(PM)通常被视为一种较不常见的扩散模式;然而,跨越所有原发肿瘤的谱系,PM的后果每年影响着大量患者。与其他转移模式不同,患者在就诊或治疗过程中常常会出现症状,这为PM的管理带来了额外的挑战。早期的化疗和不完全的外科干预虽然暂时改善了症状,但持久的症状控制和生存延长却很少见,这在20世纪的大部分时间里形成了对PM治疗无效的看法。值得注意的是,随着更好的全身治疗组合的持续发展、细胞减灭手术(CRS)的优化,以及将区域治疗(特别是热灼腹腔化疗)与CRS结合的严格研究,为PM患者提供了更有效的多模式治疗选择。在本文中,作者对高频率PM的肿瘤(包括阑尾癌、结直肠癌、间皮瘤和胃癌)所建立的现代治疗方法的数据进行了全面回顾。作者还探讨了将热灼腹腔化疗加入已建立的CRS和全身治疗模式在晚期卵巢癌中的新兴作用,以及近期临床试验识别的聚(腺苷二磷酸核糖)聚合酶维持治疗的疗效。最后,文中还包括了探索精准医学技术在PM管理中作用的最新数据,这些技术在未来可能有助于进一步改善患者选择、识别最佳全身治疗方案、检测可操作突变,并为药物开发识别新靶点。
英文摘要
Peritoneal metastasis (PM) is often regarded as a less frequent pattern of spread; however, collectively across all spectra of primary tumors, the consequences of PM impact a large population of patients annually. Unlike other modes of metastasis, symptoms at presentation or during the treatment course are common, representing an additional challenge in the management of PM. Early efforts with chemotherapy and incomplete surgical interventions transiently improved symptoms, but durable symptom control and survival extension were rare, which established a perspective of treatment futility for PM through most of the 20th century. Notably, the continued development of better systemic therapy combinations, optimization of cytoreductive surgery (CRS), and rigorous investigation of combining regional therapy-specifically hyperthermic intraperitoneal chemotherapy-with CRS, have resulted in more effective multimodal treatment options for patients with PM. In this article, the authors provide a comprehensive review of the data establishing the contemporary approach for tumors with a high frequency of PM, including appendix, colorectal, mesothelioma, and gastric cancers. The authors also explore the emerging role of adding hyperthermic intraperitoneal chemotherapy to the well established paradigm of CRS and systemic therapy for advanced ovarian cancer, as well as the recent clinical trials identifying the efficacy of poly(adenosine diphosphate ribose) polymerase maintenance therapy. Finally, recent data are included that explore the role of precision medicine technology in PM management that, in the future, may help further improve patient selection, identify the best systemic therapy regimens, detect actionable mutations, and identify new targets for drug development.
麦伴智能科研服务
主要研究问题
- 近年来在腹膜转移的管理中,系统治疗组合的具体进展是什么?
- 在不同原发肿瘤类型中,腹膜转移的治疗策略有何异同?
- 超热腹腔化疗(HIPEC)在腹膜转移患者中的应用效果如何,与传统治疗相比有哪些优势?
- 精准医学技术如何改变腹膜转移的患者选择和治疗方案?
- 未来在腹膜转移的研究中,有哪些潜在的新靶点或治疗方法值得关注?
核心洞察
1. 研究背景和目的
腹膜转移(PM)被认为是一种相对少见的转移模式,但实际上,它对所有原发肿瘤的患者群体产生了广泛的影响。PM患者在就诊时或治疗过程中常常会出现多种症状,这为管理PM带来了额外的挑战。20世纪的大部分时间里,由于化疗和不完全的外科干预仅能暂时改善症状,且无法实现持久的症状控制和生存期延长,导致对PM治疗的普遍看法是无效的。因此,本研究旨在回顾和总结近年来在PM管理领域的最新进展,探讨更有效的多模式治疗选择。
2. 主要方法和发现
本研究通过综合文献回顾,分析了近年来在PM管理中的新方法和治疗策略。重点讨论了以下几个方面:
- 更加有效的系统治疗组合的开发。
- 细胞减灭术(CRS)的优化。
- 将区域治疗(特别是热灌注腹腔化疗)与CRS相结合的临床应用。 研究涵盖了腹膜转移高发的肿瘤类型,包括阑尾癌、结直肠癌、间皮瘤和胃癌。此外,文章还探讨了在晚期卵巢癌治疗中添加热灌注腹腔化疗的潜在益处,以及聚(腺苷二磷酸核糖)聚合酶维持治疗的有效性。
3. 核心结论
现代的腹膜转移管理已从过去的治疗无效观念转变为多模式治疗的希望。通过系统治疗、CRS和区域治疗的结合,患者的症状控制和生存期有了显著改善。特别是在一些高风险肿瘤类型的治疗中,这种综合方法显示出更好的疗效。此外,精准医学技术的应用有望进一步优化患者选择、识别最佳系统治疗方案、检测可操作的突变,以及发现新的药物开发靶点。
4. 研究意义和影响
此研究为腹膜转移的管理提供了新的视角,强调了多模式治疗的重要性。随着对治疗方法的不断优化和精准医学的发展,PM患者的预后有望进一步改善。这不仅为临床实践提供了指导,也为未来研究指明了方向,鼓励进一步探索新的治疗策略和靶向药物,以应对这一复杂的临床挑战。整体而言,该研究为提高腹膜转移患者的生活质量和生存率提供了重要的科学依据。
引用本文的文献
- The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma. - Mei Feng;Hao Xu;Wenyuan Zhou;Yisheng Pan - Journal of experimental & clinical cancer research : CR (2023)
- Single-cell transcriptomics in ovarian cancer identify a metastasis-associated cell cluster overexpressed RAB13. - Jiahao Guo;Xiaoyang Han;Jie Li;Zhefeng Li;Junjie Yi;Yan Gao;Xiaoting Zhao;Wentao Yue - Journal of translational medicine (2023)
- FMO family may serve as novel marker and potential therapeutic target for the peritoneal metastasis in gastric cancer. - Xumeng Gong;Dong Hou;Shengning Zhou;Jianan Tan;Guangyu Zhong;Bing Yang;Lang Xie;Fanghai Han;Lin Zhong - Frontiers in oncology (2023)
- Th1 cells inducing IFNγ response improves immunotherapy efficacy in gastric cancer. - Qi Cao;Ruidong Xue;Ning Zhang - Chinese journal of cancer research = Chung-kuo yen cheng yen chiu (2023)
- A phase I dose-finding trial of hyperthermic intraperitoneal docetaxel combined with cisplatin in patients with advanced-stage ovarian cancer. - Zhi-Yao You;Miao-Fang Wu;Hui Li;Yan-Fang Ye;Li-Juan Wang;Zhong-Qiu Lin;Jing Li - Journal of gynecologic oncology (2024)
- A novel risk model for predicting peritoneal metastasis in colorectal cancer based on the SEER database. - Li Yao;Huan Shao;Xinyi Zhang;Xuan Huang - Journal of cancer research and clinical oncology (2023)
- Remodeling the tumor immune microenvironment via siRNA therapy for precision cancer treatment. - Lingxi Jiang;Yao Qi;Lei Yang;Yangbao Miao;Weiming Ren;Hongmei Liu;Yi Huang;Shan Huang;Shiyin Chen;Yi Shi;Lulu Cai - Asian journal of pharmaceutical sciences (2023)
- ACLY promotes gastric tumorigenesis and accelerates peritoneal metastasis of gastric cancer regulated by HIF-1A. - Zhengyuan Yan;Kanghui Liu;Peng Xu;Zhengwei Chen;Pengpeng Zhang;Shengbin Pei;Quan Cheng;Shansong Huang;Bowen Li;Jialun Lv;Zekuan Xu;Hao Xu;Li Yang;Diancai Zhang - Cell cycle (Georgetown, Tex.) (2023)
- The prophylactic role of mitomycin C-based hyperthermic intraperitoneal chemotherapy (MMC-based HIPEC) on peritoneal metastasis of spontaneously ruptured hepatocellular carcinoma (srHCC): A pilot study. - Ziqi Hou;Guoteng Qiu;Qingyun Xie;Zhaoxing Jin;Shizheng Mi;Jiwei Huang - Global health & medicine (2023)
- Real-world Study on the Effect of PARPi as Maintenance Therapy on Platinum Sensitivity after First- and Second-line Chemotherapy in Patients with Recurrent High-grade Serous Epithelial Ovarian Cancer. - Yanglong Guo;Xi Chen;Xuedong Tang;Shan Pan;Tao Zhu;Yingli Zhang - Current cancer drug targets (2024)
... (34 更多 篇文献)
© 2025 MaltSci 麦伴科研 - 我们用人工智能技术重塑科研
